Analyst Price Targets — OPTN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 21, 2025 10:12 am | — | H.C. Wainwright | $9.00 | $9.15 | TheFly | Optinose downgraded to Neutral from Buy at H.C. Wainwright |
| November 13, 2024 3:25 pm | David Amsellem | Piper Sandler | $1.00 | $0.89 | StreetInsider | Optinose (OPTN) PT Lowered to $1 at Piper Sandler |
| May 15, 2024 8:44 am | Thomas Flaten | Loop Capital Markets | $3.00 | $1.12 | StreetInsider | Optinose (OPTN) PT Lowered to $3 at Lake Street Capital Markets |
| November 14, 2022 8:32 am | — | BMO Capital | $5.00 | $2.01 | Benzinga | BMO Capital Maintains Outperform on OptiNose, Lowers Price Target to $5 |
| June 13, 2022 2:28 pm | David Amsellem | Piper Sandler | $4.00 | $2.62 | TheFly | Optinose data gives Xhance 'clear path' to label expansion, says Piper Sandler |
Latest News for OPTN
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for OPTN.
U.S. House Trading
No House trades found for OPTN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.